

Media Contact

Julien Dedman
Johnson & Johnson Innovation
+852 9022 8032
jdedman@its.jnj.com

Johnson & Johnson Innovation Announces Launch of Shanghai Lung Cancer Innovation QuickFire Challenge

- *Challenge aims to identify cutting-edge, early-stage innovation focused on all stages of lung health resulting in the prevention, interception, and cure of lung cancer*
- *Winners will receive prizes including up to US\$750,000 (approximately RMB4,775,850) in total grants, one-year residency at JLABS @ Shanghai, mentorship and coaching*

SHANGHAI, CHINA, 14 June 2018 – Johnson & Johnson Innovation, Division of Johnson & Johnson (China) Investment Ltd., today announced the launch of the Shanghai Lung Cancer Innovation QuickFire Challenge to identify new solutions for lung health and to combat lung cancer in China and around the world. Avrum Spira, Global Head, Lung Cancer Initiative, Johnson & Johnson, and Melinda Richter, Global Head, Johnson & Johnson Innovation, JLABS, made the announcement at CES Asia in Shanghai, China.

The Shanghai Lung Cancer Innovation QuickFire Challenge seeks to identify cutting-edge, early-stage innovation from around the world that addresses all stages of lung health. The competition will be open to entrepreneurs, academicians, biotech researchers and start-up companies from around the world with innovative ideas that have the potential to prevent, intercept or cure lung cancer, improving the health and wellbeing of millions of people in China and around the world.

Up to three innovators with the best idea, technology, or solution across pharmaceuticals, consumer, medical devices, global public health, and/or health technologies will be awarded up to US\$750,000 (approximately RMB4,775,850) in total grants; one-year of residency at JLABS @ Shanghai, including a laboratory bench, workstation and access to the JLABS community; and mentorship and coaching from Johnson & Johnson Innovation, the Janssen Pharmaceutical Companies of Johnson & Johnson, and/or affiliate experts. The winners will be announced in Spring 2019 at the grand opening of the JLABS @ Shanghai in Shanghai, China.

“We aim to create a world without disease, and our efforts in China are part of our commitment to identify and nurture the best internal and external science to transform one of the world’s most prevalent and deadly forms of cancer into a preventable and curable disease,” said Avrum Spira, Global Head of Lung Cancer Initiative, Johnson & Johnson. “Through the QuickFire Challenge, we hope to discover innovative solutions to reduce the burden of lung cancer and make a real difference in lung health in China and globally.”

Lung cancer is a major cause of global morbidity and mortality with approximately 1.6 million deaths each year. China is disproportionately impacted by lung cancer, where it has been the leading cause of cancer death since 2010¹, and maintains the highest lung cancer prevalence and death rate in the world²

¹ [Medical Daily: Lung Cancer Most Common Cancer In China: Air Pollution Taking Its Toll With Estimates Of 7,500 Deaths Per Day](#)

² [China Daily: Lung cancer patients to number 800,000 per year by 2020](#)

with nearly 4.3 million new cancer patients and 730,000 cases of lung cancer in 2015 alone, accounting for nearly 36 percent of the world's total³. Compounding the problem of high incidence is low survival rates.

With significant exposure to air pollution and high levels of smoking among the general population, it is predicted that 700,000 Chinese will die from lung cancer each year by 2020², and new lung cancer cases will reach 7.4 million per year among adults aged 40+ by 2030. To address this major clinical and economic need, a new approach to addressing this disease is needed in China and around the world. The QuickFire Challenge is designed to help address this problem and support the Chinese government's Healthy China 2030 initiative and its ambitious objectives to reduce the population of smokers and to increase the overall five-year survival rate of patients suffering from various cancers.

“We are excited to bring the QuickFire Challenge to China for the first time. China is playing an increasing role in the global healthcare innovation system by leveraging competitive advantages including talent, scale, speed, financing options and an enabling policy environment,” said Melinda Richter, Global Head of Johnson & Johnson Innovation, JLABS. “In line with the vision of the new and upcoming JLABS @ Shanghai, where the winners will be offered residency, we believe a good idea can come from anywhere, and it's our goal to find new and innovative technologies that provide solutions to people globally. Working together, we can spark the next great idea to change the trajectory of health.”

The QuickFire Challenge welcomes submissions from June 14 to September 14, 2018. For more information about the Shanghai Lung Cancer Innovation QuickFire Challenge (including the terms and conditions of entry), please visit: <http://jllabs.tv/lungs>

###

About Johnson & Johnson Innovation

Johnson & Johnson Innovation focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson's global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers, JLABS, Johnson & Johnson Innovation - JJDC, Inc. and our Business Development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. For more information please visit www.jnjinnovation.com.

About Johnson & Johnson Innovation, JLABS

Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS we value great ideas and are passionate

³ [Reuters: China lung cancer on rise, smog suspected - China Daily](#)

about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and digital health sectors.

JLABS currently has eight locations in innovation hot spots across North America and produces entrepreneurial programs and campaigns to seek out the best science, like the QuickFire Challenges around the globe. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then, has established two locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility in South San Francisco. JLABS is also located in Boston through a collaboration with LabCentral, in Lowell, Massachusetts through a collaboration with UMass, in Houston through a collaboration with the Texas Medical Center (TMC), and in Toronto through a collaboration with the Ontario Government and the University of Toronto. A new JLABS @ NYC (in collaboration with the New York Genome Center) is planned to open in 2018 and the new JLABS @ Shanghai is expected to open in Q2, 2019.